INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information: Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
May 20, 2003
April 24, 2020
f47444ad-ffd7-42ea-816d-1d6da8a15bf1
Related Documents
ANDAs:Pharmaceutical Solid Polymorphism: Chemistry, Manufacturing, and Controls Information: Guidance for Industry
Guidance DocumentJuly 9, 2007Center for Drug Evaluation and Research
Nonclinical Safety Evaluation of Pediatric Drug Products
Guidance DocumentFebruary 15, 2006Center for Drug Evaluation and Research
Drug Products Containing Ensulizole, Hypromellose, Meradimate, Octinoxate, and Octisalate — Labeling Enforcement Policy
Guidance DocumentJune 3, 2003Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.